Balyasny Asset Management’s Moderna MRNA Stock Holding History

Balyasny Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-38,800	Closed	-$1.14M	–	3283
2025 Q4	$1.14M	Buy	38,800 +17,800	+85%	+$484K	﹤0.01%	2126
2025 Q3	$542K	Buy	+21,000	New	+$586K	﹤0.01%	2366
2025 Q2	–	Sell	-411,900	Closed	-$11.7M	–	3158
2025 Q1	$11.7M	Buy	411,900 +396,500	+2,575%	+$14.1M	0.02%	829
2024 Q4	$640K	Sell	15,400 -43,500	-74%	-$2.08M	﹤0.01%	2105
2024 Q3	$3.94M	Buy	58,900 +14,200	+32%	+$1.3M	0.01%	1373
2024 Q2	$5.31M	Buy	44,700 +24,700	+124%	+$3.13M	0.01%	1141
2024 Q1	$2.13M	Buy	+20,000	New	+$2.02M	﹤0.01%	1527
2023 Q3	–	Sell	-3,800	Closed	-$462K	–	2554
2023 Q2	$462K	Buy	+3,800	New	+$507K	﹤0.01%	1875
2021 Q4	–	Sell	-192,000	Closed	-$73.9M	–	2478
2021 Q3	$73.9M	Sell	192,000 -590,700	-75%	-$218M	0.31%	52
2021 Q2	$184M	Buy	782,700 +509,700	+187%	+$91.1M	0.87%	7
2021 Q1	$35.7M	Buy	273,000 +168,000	+160%	+$24.3M	0.18%	135
2020 Q4	$11M	Buy	+105,000	New	+$10.6M	0.06%	412

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's MRNA Position: Q1 2026 in Review

Balyasny Asset Management reduced its Moderna (MRNA) stake by 62% in Q1 2026, selling an estimated $401K and leaving 5,191 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Balyasny Asset Management first reported a position in MRNA in Q2 2019 and has held it in 15 quarters since. The position peaked at $72.3M in Q3 2023. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Balyasny Asset Management held 5,191 shares of Moderna worth $264K as of Q1 2026.
Balyasny Asset Management sold 8,599 Moderna shares in Q1 2026, an estimated $401K.
Moderna made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2611 holding.
Balyasny Asset Management first reported a position in Moderna in Q2 2019 and has held it in 15 quarters since.
Balyasny Asset Management's Moderna position peaked at $72.3M in Q3 2023.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.